28112685|t|Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy
28112685|a|Parkinson's disease (PD) patients experience loss of normal motor function (hypokinesia), but can develop uncontrollable movements known as dyskinesia upon treatment with L-DOPA. Poverty or excess of movement in PD has been attributed to overactivity of striatal projection neurons forming either the indirect (iSPNs) or the direct (dSPNs) pathway, respectively. Here, we investigated the two pathways ' contribution to different motor features using SPN type-specific chemogenetic stimulation in rodent models of PD (PD mice) and L-DOPA-induced dyskinesia (LID mice). Using the activatory Gq-coupled human M3 muscarinic receptor (hM3Dq), we found that chemogenetic stimulation of dSPNs mimicked, while stimulation of iSPNs abolished the therapeutic action of L-DOPA in PD mice. In LID mice, hM3Dq stimulation of dSPNs exacerbated dyskinetic responses to L-DOPA, while stimulation of iSPNs inhibited these responses. In the absence of L-DOPA, only chemogenetic stimulation of dSPNs mediated through the Gs-coupled modified rat muscarinic M3 receptor (rM3Ds) induced appreciable dyskinesia in PD mice. Combining D2 receptor agonist treatment with rM3Ds-dSPN stimulation reproduced all symptoms of LID. These results demonstrate that dSPNs and iSPNs oppositely modulate both therapeutic and dyskinetic responses to dopamine replacement therapy in PD. We also show that chemogenetic stimulation of different signaling pathways in dSPNs leads to markedly different motor outcomes. Our findings have important implications for the design of effective antiparkinsonian and antidyskinetic drug therapies.
28112685	0	24	Chemogenetic stimulation	T044	C1148560
28112685	28	55	striatal projection neurons	T025	C0027882
28112685	56	65	modulates	UnknownType	C0544633
28112685	66	75	responses	T032	C0871261
28112685	79	98	Parkinson's disease	T047	C0030567
28112685	99	106	therapy	T061	C0087111
28112685	107	126	Parkinson's disease	T047	C0030567
28112685	128	130	PD	T047	C0030567
28112685	132	140	patients	T101	C0030705
28112685	141	151	experience	T041	C0596545
28112685	152	181	loss of normal motor function	T033	C1864672
28112685	183	194	hypokinesia	T033	C0086439
28112685	213	237	uncontrollable movements	T047	C0013384
28112685	247	257	dyskinesia	T047	C0013384
28112685	263	272	treatment	T061	C0087111
28112685	278	284	L-DOPA	T116,T121,T123	C0023570
28112685	286	293	Poverty	T102	C0032854
28112685	307	315	movement	T040	C0026649
28112685	319	321	PD	T047	C0030567
28112685	345	357	overactivity	T033	C1536696
28112685	361	388	striatal projection neurons	T025	C0027882
28112685	418	423	iSPNs	T025	C0027882
28112685	440	445	dSPNs	T025	C0027882
28112685	447	454	pathway	T023	C0027792
28112685	500	508	pathways	T023	C0027792
28112685	537	542	motor	T025	C0026609
28112685	543	551	features	T080	C2348519
28112685	558	600	SPN type-specific chemogenetic stimulation	T044	C1148560
28112685	604	617	rodent models	T050	C1519106
28112685	621	623	PD	T047	C0030567
28112685	625	627	PD	T047	C0030567
28112685	628	632	mice	T015	C0025929
28112685	638	663	L-DOPA-induced dyskinesia	T033	C3552620
28112685	665	668	LID	T033	C3552620
28112685	669	673	mice	T015	C0025929
28112685	686	736	activatory Gq-coupled human M3 muscarinic receptor	T116,T192	C0289799
28112685	738	743	hM3Dq	T116,T192	C0289799
28112685	760	784	chemogenetic stimulation	T044	C1148560
28112685	788	793	dSPNs	T025	C0027882
28112685	810	821	stimulation	T044	C1148560
28112685	825	830	iSPNs	T025	C0027882
28112685	845	863	therapeutic action	T038	C2712171
28112685	867	873	L-DOPA	T116,T121,T123	C0023570
28112685	877	879	PD	T047	C0030567
28112685	880	884	mice	T015	C0025929
28112685	889	892	LID	T033	C3552620
28112685	893	897	mice	T015	C0025929
28112685	899	904	hM3Dq	T116,T192	C0289799
28112685	905	916	stimulation	T044	C1148560
28112685	920	925	dSPNs	T025	C0027882
28112685	938	958	dyskinetic responses	T032	C0871261
28112685	962	968	L-DOPA	T116,T121,T123	C0023570
28112685	976	987	stimulation	T044	C1148560
28112685	991	996	iSPNs	T025	C0027882
28112685	997	1006	inhibited	T080	C0311403
28112685	1013	1022	responses	T032	C0871261
28112685	1042	1048	L-DOPA	T116,T121,T123	C0023570
28112685	1055	1079	chemogenetic stimulation	T044	C1148560
28112685	1083	1088	dSPNs	T025	C0027882
28112685	1110	1156	Gs-coupled modified rat muscarinic M3 receptor	T116,T192	C0289799
28112685	1158	1163	rM3Ds	T116,T192	C0289799
28112685	1165	1172	induced	T169	C0205263
28112685	1185	1195	dyskinesia	T047	C0013384
28112685	1199	1201	PD	T047	C0030567
28112685	1202	1206	mice	T015	C0025929
28112685	1218	1229	D2 receptor	T116,T192	C0058698
28112685	1230	1237	agonist	T121	C2987634
28112685	1238	1247	treatment	T169	C1522326
28112685	1253	1275	rM3Ds-dSPN stimulation	T044	C1148560
28112685	1291	1299	symptoms	T184	C1457887
28112685	1303	1306	LID	T033	C3552620
28112685	1339	1344	dSPNs	T025	C0027882
28112685	1349	1354	iSPNs	T025	C0027882
28112685	1366	1374	modulate	UnknownType	C0544633
28112685	1380	1416	therapeutic and dyskinetic responses	T032	C0871261
28112685	1420	1428	dopamine	T109,T121,T123	C0013030
28112685	1429	1448	replacement therapy	T061	C0279033
28112685	1452	1454	PD	T047	C0030567
28112685	1474	1498	chemogenetic stimulation	T044	C1148560
28112685	1512	1530	signaling pathways	T044	C0037080
28112685	1534	1539	dSPNs	T025	C0027882
28112685	1568	1582	motor outcomes	T080	C0085415
28112685	1588	1596	findings	T169	C2607943
28112685	1653	1703	antiparkinsonian and antidyskinetic drug therapies	T061	C0013216